Navigation Links
Sangamo BioSciences Reports Third Quarter 2009 Financial Results
Date:11/4/2009

lion to $10.0 million, up to a total of $25.0 million, based upon cumulative product sales.
  • Announcement of a second Phase 1 clinical trial of SB-728-T for the treatment of HIV/AIDS. In September 2009, Sangamo announced the successful review and acceptance by the FDA of an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the company's ZFP nuclease (ZFN)-based therapeutic, SB-728-T. A single dose Phase 1 clinical study of SB-728-T was initiated in February 2009 and is ongoing at the University of Pennsylvania. Both Phase 1 studies are designed primarily to evaluate the safety and tolerability of this ZFP Therapeutic approach. However, subjects' CD4 T-cell counts, levels of CCR5-modified T-cells and viral burden will also be monitored.
  • Publication of ground-breaking new ZFN-mediated gene editing applications in stem cells. Scientists from The Whitehead Institute led by Dr. Rudolf Jaenisch used ZFNs designed by Sangamo to efficiently and precisely modify the genomes of human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs). Human ESCs and iPSCs are useful tools in drug discovery and development. Scientists also hope to use these cells therapeutically in transplantation medicine and other regenerative applications. The research was described in a paper published in the scientific journal Nature Biotechnology (Nat Biotechnol. 2009 Sep; 27(9):851-7).
  • Sangamo's collaborators awarded significant clinical research awards to advance research into potential ZFP Therapeutics. Sangamo's collaborators at the City of Hope and University of Southern California were awarded a $14.5 million grant from the California Institute of Regenerative Medicine (CIRM). The grant will support the development of a ZFN-based stem cell therapy for HIV/AIDS. In addition, research led by Donald B. Kohn, M.D., Director of the UCLA Human Gene
    '/>"/>

  • SOURCE Sangamo BioSciences, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine news :

    1. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
    2. Sangamo BioSciences Provides Update on Companys Accomplishments in 2007 and 2008 Objectives
    3. Sangamo BioSciences Reports First Quarter 2009 Financial Results
    4. Sangamo BioSciences Announces Presentation at the JMP Securities Research Conference
    5. Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009
    6. Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting
    7. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
    8. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
    9. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
    10. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
    11. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. ... cells grow may help doctors diagnose and treat the most ... have found that the deadliest skin cancers occur most often ... long history of sun exposure. These lesions also grow ... cell growth -- called "high mitotic rate" -- is ...
    (Date:8/20/2014)... one of the most persistent and deadliest infectious diseases ... each year. , Scientists who study tuberculosis have long ... spread from humans in Africa to seals and sea ... transmitted it to Native people there before Europeans landed ... Reveal Seals as a Source of New World Human ...
    (Date:8/20/2014)... York (PRWEB) August 20, 2014 As ... use of power morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in ... that two U.S. Senators from New York are urging ... a recall of the devices. In a letter dated ... Democrats, also implored the agency to seriously consider the ...
    (Date:8/20/2014)... the amygdala stimulates stress responses in adults, researchers ... have found that the amygdala has an inhibitory ... of nonhuman primates. , The results are published ... , The amygdala is a region of the ... threatening situations and learning about threats. Alterations in ...
    (Date:8/20/2014)... HealthDay Reporter TUESDAY, Aug. 19, 2014 ... baby,s immune system is twice as common as once believed, ... This is the first evaluation of the effect of ... severe combined immunodeficiency (SCID), or "Bubble Boy" disease, the researchers ... the boy in the bubble, who was born without an ...
    Breaking Medicine News(10 mins):Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 2Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 3Health News:New research shows seals and sea lions likely spread tuberculosis to humans 2Health News:New research shows seals and sea lions likely spread tuberculosis to humans 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 4Health News:Maturing brain flips function of amygdala in regulating stress hormones 2Health News:Maturing brain flips function of amygdala in regulating stress hormones 3Health News:'Bubble Boy' Disease May Be More Common Than Thought 2Health News:'Bubble Boy' Disease May Be More Common Than Thought 3
    ... years, the Tower of London has had an iconic status ... it is facing a major pollution threat. ... cars and trucks, and the discoloration is most noticeable at ... William the Conqueror in 1078, says study co-author Peter Brimblecombe, ...
    ... is of the view that glycerin, a by-product of bio-diesel, ... , ,In his study, Monty Kerley, a professor of ... effectiveness of glycerin as cattle feed. ,Through ... from various breeds to determine if bio-leftovers provide a healthy ...
    ... died of anthrax in Orissa's tribal dominated Koraput district, ... last two days, health officials said Friday. ... Jani, 35, of Padiguda village under Semliguda block in ... disease reportedly after consuming cattle meat. ,K.H. ...
    ... reinstated as executive director of the Escorts hospital here ... the hospital announced Saturday. ,Fortis Healthcare, which ... Institute and Research Centre (EHIRC), Saturday withdrew the police ... sacking last week as a "result of misunderstanding". ...
    ... the Department of Chemical Engineering makes it possible to remove ... The process is based on biosorption, which is a ... can be used to purify water from painting, tannery or ... whenever olive oil is obtained: what can we do with ...
    ... Results from an international multi-center Phase II clinical ... effective in treating patients with clinically active ... are refractory to immunosuppressants and/or anti-TNF agents. A ... treatment was noted in the study, using standard ...
    Cached Medicine News:Health News:Study Finds Glycerin to Be a Good Source for Cattle Feed 2Health News:Naresh Trehan Reinstated as Chief of Escorts After Weeklong Row 2Health News:Olive Stones to Depollute Industrial Sewage Water 2Health News:ECP may Be Effective in Treating Crohn's Disease 2
    (Date:8/20/2014)... 2014  Amerigen Pharmaceuticals Ltd. announces that its ... received Chinese FDA (CFDA) approval and has subsequently ... the China domestic market.  ... agreement with Sinochem Jiangsu Pharmaceutical Co., Ltd., Amerigen ... approved and China CFDA certified oral solid dose ...
    (Date:8/20/2014)... WORTH, Fla. , Aug. 20, 2014  Glades Drugs, ... , is proud to announce its expansion into a ... , which will feature an 8,000-square-foot office space and state ... currently accepting applications for 100 open positions for the new ... at 4560 Lantana Road will serve as the chain,s corporate ...
    (Date:8/20/2014)... , Aug. 20, 2014 Trovagene, Inc. (NASDAQ: ... today that results from two clinical studies will be ... the Company,s urine-based diagnostic test for the detection of ... conference is scheduled to take place in ... 25 th . Additionally, a new U.S. patent was ...
    Breaking Medicine Technology:Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2Glades Drugs Moves to New Corporate Headquarters, 100 Open Positions 2Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    Medicine Products: